AplusA 30+ years Anniversary - Interview #1
In ‘21, we are celebrating our 30+.
AplusA is actually 30+ years old this year... But what does it mean to be in business for over 30 years?
AplusA Anniversaire 30+ ans - Interview #1
C’est l’année 21, mais nous en célébrons plus de 30.
En 2021, AplusA fête - non pas ses 30 -...
Our brand new 2020 Syndicated Surveys
Our range of syndicated studies now covers over 30 indications, many of them with results...
COVID-19 2nd Phase - Impact on Physicians’ Practice - Syndicated Study
hemato-oncology, COVID-19, Syndicated Studies, Oncology
How does COVID-19 affect the HCPS relationships with patients and with the pharmaceutical...
mRCC: promising new combinations lead to disruption in L1 and L2
Targeted therapies, particularly tyrosine kinase inhibitors (TKI) dominate the treatment of...
COVID-19 road to recovery: 5 key insights from our syndicated study
As the global number of infected cases surpasses 46 million (Nov 2, 2020), there is a non-stop...
Social Media Insights: ASCO 2020 Part 2
The American Society of Oncologists (ASCO) annual meeting is a major fixture in the global...
Welcoming the new-look AplusA website!
You might have noticed that our site looks a little different. We wanted to share the story...
DLBCL Patient Insights in the US and EU5
When working on a new or existing brand within the DLBCL market it's important to have up to...
Social Media Insights: ASCO 2020 Part 1
The American Society of Oncologists (ASCO) annual meeting is a major fixture in the global...